Treats moderately to severely active rheumatoid arthritis. Sold as Cimzia. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Certolizumab Pegol (sold as Cimzia), first approved Apr 22, 2008, with 8 new uses approved and 0 published complete response letters.
| Cimzia | Part B | $362M | -9% | 26,276 |
| Cimzia (2 Pack) | Part D | $304M | +15% | 6,518 |
| Cimzia | Part D | $20.6M | +5% | 1,132 |
| Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel DiseaseIBD (Inflammatory Bowel Disease), Crohn Disease (CD) · Shmuel Kivity, MD | — | Recruiting | Jun 12, 2026 |
| Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained RemissionTakayasu Arteritis · Marmara University | Not applicable | Recruiting | Mar 25, 2026 |
| Utilization of a Microdevice for Psoriasis and Atopic DermatitisPsoriasis, Atopic Dermatitis · University of California, San Francisco | Phase 4 | Not yet recruiting | Jan 20, 2026 |
| A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular BiomarkersPsoriasis, Psoriasis Arthritis · Taichung Veterans General Hospital | Phase 4 | Recruiting | Sep 2, 2025 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRheumatic Disease · NYU Langone Health | Phase 2 | Recruiting | Aug 24, 2025 |
| SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS) · Leiden University Medical Center | — | Recruiting | Jun 15, 2025 |
| Certolizumab in Recurrent Implantation Failure (RIF)Recurrent Unexplained Implantation Failure · Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Jul 5, 2023 |
| Stand UP to Rheumatoid Arthritis (SUPRA)Rheumatoid Arthritis · Marie Hudson, MD | Not applicable | Recruiting | Mar 31, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
